Redashing guidelines for late-onset male hypogonadism, the Spanish Society of Endocrinology and Nutrition and the Spanish Association of Urology issued a unified diagnostic framework to standardize identification and curb unnecessary treatments, farmacosalud.com reported.
The updated framework replaces a consensus published 16 years ago. It introduces an explicit diagnostic algorithm that combines biochemical confirmation with etiological orientation, specifically addressing the challenge of overlapping symptoms between the condition and normal physiological aging.
“One of the main challenges of age-associated male hypogonadism is to differentiate it from the changes typical of aging and from other diseases that can present similar symptoms,” said Mireia Mora Porta, member of the Gonads, Identity and Sexual Differentiation Working Group and first author of the document, told farmacosalud.com.
The updated protocol establishes three clear total testosterone decision thresholds to guide clinical evaluation. A total testosterone level above 12 nanomoles per liter rules out the condition entirely.
Levels falling between 8 and 12 nanomoles per liter require supplementary calculation of free testosterone. Readings dropping below 8 nanomoles per liter establish a probable and highly suggestive diagnosis, which must be confirmed with a repeat blood draw taken two to four weeks later.
Screening is restricted to patients exhibiting compatible symptoms alongside specific predisposing conditions. These conditions include type 2 diabetes, severe excess weight, metabolic syndrome, osteoporosis, chronic kidney disease, human immunodeficiency virus involving weight loss, chronic obstructive pulmonary disease, infertility, and pituitary pathologies.
Clinical data underpinning the consensus highlight a heavy overlap between testosterone deficiency and metabolic disease. Between 30% and 50% of men diagnosed with type 2 diabetes or metabolic syndrome experience hypogonadism, while obese men show testosterone concentrations roughly 30% lower than their lean peers.
Before prescribing hormone replacement therapy, clinicians must evaluate and manage reversible contributors. The guidelines outline four primary intervention lines: lifestyle modification, weight loss for overweight individuals, medication reviews to eliminate interfering drugs, and careful management of opioids, chronic glucocorticoids, and anabolic agents.
When hormone replacement is indicated, the document supports individualized regimens utilizing short-acting injectables, long-acting injectables, or transdermal gels. For older or frail patients, the guidelines suggest a six-month therapeutic trial using transdermal testosterone gels because this formulation permits rapid discontinuation if adverse effects emerge.
“Not all symptoms associated with male aging respond to a testosterone deficit, nor do all patients with low levels of this hormone need treatment,” said Josep Torremadé, coordinator of the Andrology Working Group of the Spanish Association of Urology, told farmacosalud.com.
Torremadé also cautioned against the growing use of testosterone in non-medical settings for aesthetic or athletic enhancement. “Its administration must always respond to a clear medical indication, based on a confirmed diagnosis and accompanied by adequate follow-up,” he told farmacosalud.com.
Testing is restricted to individuals presenting with compatible symptoms—such as reduced morning erections, low libido, and fatigue—who also have specific concurrent conditions like type 2 diabetes, obesity, or metabolic syndrome.
A diagnosis is highly probable when total testosterone levels fall below 8 nanomoles per liter, provided the low reading is verified by a second blood draw taken two to four weeks later.
Transdermal formulations allow clinicians to suspend treatment easily if adverse effects occur during a trial period, making them particularly useful for older or frail individuals.
Related reading